ImmunoPrecise Antibodies's total assets for Q3 2025 were C$45.53M, a decrease of -24.06% from the previous quarter. IPA total liabilities were C$20.41M for the fiscal quarter, a -25.20% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.